ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1180

Multicenter Study on the Rate of Renal Function Deterioration in IgG4-Related Tubulointerstitial Nephritis

Mitsuhiro Kawano1, Ichiro Mizushima2, Takahiro Matsunaga1, Kazunori Yamada3, Satoshi Hara1, Hiroshi Fujii1, Takako Saeki4, Yoshinori Taniguchi5 and Hitoshi Nakashima6, 1Division of Rheumatology, Kanazawa University Hospital, Kanazawa, Japan, 2Kanazawa University Hospital, Kanazawa, Japan, 3Department of Advanced Research in Community Medicine, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan, 4Department of Internal Medicine, Nagaoka Red Cross Hospital, Nagaoka, Japan, 5Department of Endocrinology, Metabolism, Nephrology and Rheumatology, Kochi Medical School, Kochi, Japan, 6Div of Nephrol & Rheumatol, Dept of Int Med, Faculty of Medicine, Fukuoka University, Fukuoka, Japan

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: IgG4 Related Disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Only a few reports have focused on the rate of renal function deterioration in IgG4-related tubulointerstitial nephritis (IgG4-TIN). Some cases show acute or progressive chronic renal failure, and others progression of renal failure slowly over one year or more. This study aimed to investigate the rate of renal function deterioration in patients with biopsy proven IgG4-TIN, leading to clarification of the divergence of the deterioration rate of renal function, identifying the factors affecting the deterioration rate, and confirming the influence of the deterioration rate on the final renal function of each case.

Methods: We extracted 18 patients with IgG4-TIN between July 2006 and March 2017 in four hospitals. Based on the rate of renal function deterioration using estimated glomerular filtration rate (eGFR) before starting corticosteroid therapy, we divided them into a rapidly deteriorating group (deterioration rate more than or equal to 4 ml/min/1.73m2/month) (n=8) and a slowly deteriorating group (deterioration rate less than 4 ml/min/1.73m2/month) (n=10), and retrospectively analyzed various clinical features (age, sex, serum IgG levels, serum IgG4 levels, serum IgE levels, serum complement levels, serum eGFR levels at start of corticosteroid and the last visit, initial dose of prednisolone, multiple organ lesions) during the clinical course in the two groups.

Results: The mean age of the 18 patients was 69 years (range: 43 to 81 years). 89% of the patients were male. The average number of affected organs was 4 (range: 1 to 9). All patients had elevated serum IgG4 levels, and average was 977 mg/dL (range: 207 to 2800). In all patients, the diagnosis of IgG4-TIN was made by histopathological confirmation of the kidney biopsy specimen with immunostaining. The mean kidney function decline rate per month before starting corticosteroid therapy was 4.4 ml/min /1.73m2/month. In seven cases, the deterioration rate of kidney function was less than 2 ml/min/1.73m2/month, while 10 cases had a rapid deterioration rate more than 4 ml/min/1.73m2/month. Corticosteroid was effective in all cases, and average recovery of eGFR after corticosteroid therapy was 17.4 ml/min/1.73m2 (range: -0.4 to 46.5). In group A (a slowly deteriorating group), the recovery of eGFR was less than that in group B (a rapidly deteriorating group) (6.4 ml/min/1.73m2 vs. 26.3 ml/min/1.73m2, P < 0.05). Hypocomplementemia was more frequent in patients in group A than those in group B (P < 0.05). No differences were noted regarding gender, age, eGFR before starting corticosteroid therapy, eGFR at the last visit, the number of affected organs, eosinophil count, serum IgG levels, IgG4, or IgE between the groups.

Conclusion: Regarding the deterioration rate of renal function before corticosteroid therapy in patients with IgG4-TIN, there are two groups, i.e. a rapidly deteriorating group and slowly deteriorating group. Hypocomplementemia is associated with the rapid deterioration of renal function, and a slowly deteriorating group shows lower recovery of renal function after the corticosteroid therapy.


Disclosure: M. Kawano, None; I. Mizushima, None; T. Matsunaga, None; K. Yamada, None; S. Hara, None; H. Fujii, None; T. Saeki, None; Y. Taniguchi, None; H. Nakashima, None.

To cite this abstract in AMA style:

Kawano M, Mizushima I, Matsunaga T, Yamada K, Hara S, Fujii H, Saeki T, Taniguchi Y, Nakashima H. Multicenter Study on the Rate of Renal Function Deterioration in IgG4-Related Tubulointerstitial Nephritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/multicenter-study-on-the-rate-of-renal-function-deterioration-in-igg4-related-tubulointerstitial-nephritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/multicenter-study-on-the-rate-of-renal-function-deterioration-in-igg4-related-tubulointerstitial-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology